Dexcom Inc
NASDAQ:DXCM

Watchlist Manager
Dexcom Inc Logo
Dexcom Inc
NASDAQ:DXCM
Watchlist
Price: 72.83 USD -2.19% Market Closed
Market Cap: 28.4B USD
Have any thoughts about
Dexcom Inc?
Write Note

Dexcom Inc
Other Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dexcom Inc
Other Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Equity CAGR 3Y CAGR 5Y CAGR 10Y
Dexcom Inc
NASDAQ:DXCM
Other Equity
$63.4m
CAGR 3-Years
256%
CAGR 5-Years
129%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Other Equity
$25.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Other Equity
-$128m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Other Equity
-$545m
CAGR 3-Years
13%
CAGR 5-Years
0%
CAGR 10-Years
-21%
Abbott Laboratories
NYSE:ABT
Other Equity
-$8.1B
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Intuitive Surgical Inc
NASDAQ:ISRG
Other Equity
$23.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
37%
No Stocks Found

Dexcom Inc
Glance View

Market Cap
28.4B USD
Industry
Health Care

Dexcom Inc. is a pioneering company at the forefront of diabetes management, focusing on continuous glucose monitoring (CGM) systems that empower individuals with diabetes to better manage their condition. Founded in 1999, Dexcom revolutionized the way patients track their glucose levels by offering real-time data through wearable sensor technology. This innovation not only enhances the quality of life for users by providing insights into their glucose fluctuations but also improves clinical outcomes, as patients can make informed decisions about their diet, exercise, and medication. With a firm commitment to research and development, Dexcom continuously invests in advanced technologies, such as smart devices and integrated platforms, to stay ahead in a competitive market. For investors, Dexcom presents a compelling opportunity given its strong growth trajectory and expanding market reach. The company has seen robust revenue growth, fueled by increasing diabetes prevalence and a shift towards more proactive health management solutions. Dexcom's strategic partnerships with major healthcare players and integrations with mobile applications further enhance its market position. As healthcare evolves, the demand for seamless and user-friendly monitoring solutions is likely to rise, placing Dexcom in a prime position to capitalize on this growing trend. With strong intellectual property, a loyal customer base, and a focused vision for future innovation, Dexcom stands as a promising investment for those looking to enter the healthcare sector.

DXCM Intrinsic Value
42.11 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Dexcom Inc's Other Equity?
Other Equity
63.4m USD

Based on the financial report for Sep 30, 2024, Dexcom Inc's Other Equity amounts to 63.4m USD.

What is Dexcom Inc's Other Equity growth rate?
Other Equity CAGR 5Y
129%

The average annual Other Equity growth rates for Dexcom Inc have been 256% over the past three years , 129% over the past five years .

Back to Top